Navigation Links
ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Date:9/9/2009

RANCHO CORDOVA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the fourth quarter and all of fiscal 2009.

For the quarter ended June 30, 2009, the Company reported revenues of $4.0 million. This compares with revenues of $7.2 million in the fourth quarter a year ago. As the Company indicated previously, revenues in the fourth quarter of fiscal 2009 were impacted by several factors, including delays in customer capital equipment purchases of its BioArchive((R)) System and reduced sales of AXP(TM) AutoXpress(TM) (AXP(TM)) bag sets due to the timing of orders from GE Healthcare. The Company expects these AXP orders will be recovered during the first two quarters of fiscal 2010.

Total disposable revenues were $2.2 million versus $4.2 million in the fourth quarter of fiscal 2008. Disposable revenues in the fourth quarter of fiscal 2009 were impacted by the factors outlined above, offset by revenues from sales of disposables for the Company's MarrowXpress(TM), or MXP(TM), which was launched in mid-fiscal 2009.

The company reported a net loss of $3.1 million, or $0.05 per share, versus a net loss of $2.5 million, or $0.04 per share, in the same period a year ago. As the Company indicated in its press release of August 6, 2009, the loss in the fourth quarter of fiscal 2009 included a number of non-recurring costs. They totaled approximately $1.8 million, including non-cash charges of approximately $0.9 million. Non-recurring charges included $0.8 million in reserves related to the transition to an upgraded AXP device and disposable as well as write-downs of obsolete inventory and tooling at AXP bag set suppliers. Non-recurri
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will webcast its ... on Monday, April 21, 2008 at 8:30 a.m. ET/5:30,a.m. ... will lead the call. On the same date pre-market, ... 2008., The call will be webcast live through ...
... 15 Excalibur, the new,international investment house launched ... of PIramed to Roche., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 ... Roche for $185 million means a ,very substantial,cash ... fund created by Sir,Christopher five years ago., ...
... CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... by Dr. Anders,Kolb of the Nemours Center for ... for Pediatric Sarcomas" was,presented today at the American ... is being held in San Diego, California from,April ...
Cached Biology Technology:Amylin Pharmaceuticals to Webcast First Quarter Results 2Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors 2Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:4/24/2014)... Initial treatment for a brain infection caused by fungus could ... due to study by University of Liverpool scientists. , ... often fatal but are relatively neglected in medical research. ... Africa, Australasia and South East Asia and mainly affect people ... people a year. , The University research team has tested ...
(Date:4/24/2014)... Researchers from North Carolina State University and the University ... new ultrasound device that could help identify arterial plaque ... causing heart attack or stroke. , At issue is ... age. Some types of plaque are deemed "vulnerable," meaning ... artery wall and cause heart attack or stroke. , ...
(Date:4/24/2014)... home from Iraq and Afghanistan, post-traumatic stress disorder (PTSD) ... and the culture at-large. Estimates indicate that as many ... Afghanistan suffer from PTSD. New research from the University ... on how PTSD is linked to other diseases in ... has implications beyond the impact of the psychiatric disorder ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3
... 2013 -- In January 2012, the United States Department ... make school lunches more nutritious, which included requiring schools ... either a fruit or vegetable with their purchased lunch. ... healthier lunches. In a new study scheduled for ...
... TAMPA, Florida (Feb. 21, 2013) Cardiovascular disease specialists at ... Research Institute affiliated with the University of South Florida announced ... testing a novel gene therapy for the treatment of heart ... regeneration of heart tissue by encouraging the body to deploy ...
... tissue and organ transplantation for diseases that are caused ... ethical discussions surrounding human embryonic stem cells, a lot ... (iPS cells). However, before this technique can be applied ... safety and efficacy of such iPS cells. VIB scientists ...
Cached Biology News:Smarter lunchrooms make lunch choices child's play 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3Cell therapy a little more concrete thanks to VIB research 2
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
Request Info...
Request Info...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Biology Products: